Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024

The global chemotherapy-induced nausea and vomiting (cinv) market has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

The global chemotherapy-induced nausea and vomiting (cinv) market is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

The increasing incidence of cancer is set to drive the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the foreseeable future. The proliferation of cancer occurs when certain cells in the body undergo uncontrolled growth and spread to other parts of the body. With cancer cases on the rise, there is a growing impetus to develop more effective and targeted antiemetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on managing CINV has led to advancements in understanding its underlying mechanisms and the creation of innovative therapies. For example, as of January 2023, the American Cancer Society (ACS) anticipates around 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer-related deaths (about 1,670 deaths per day) in the United States for 2023. Consequently, the increasing prevalence of cancer will be a driving force behind the chemotherapy-induced nausea and vomiting (CINV) market.

The growing presence of supportive regulatory initiatives is poised to propel the growth of the chemotherapy-induced nausea and vomiting (CINV) market in the coming years. Regulatory initiatives represent actions taken by regulatory bodies to formulate, execute, or enforce regulations. These initiatives are instrumental in enhancing the prevention and management of chemotherapy-induced nausea and vomiting (CINV) by guiding the development and implementation of prevention and management protocols. For instance, in May 2021, the Food and Drug Administration, a U.S.-based federal agency responsible for safeguarding public health, introduced a draft guidance for industry stakeholders to assist in the clinical development of medications designed for the treatment of CINV in adults. Therefore, the increasing prevalence of favorable regulatory initiatives is fostering the growth of the chemotherapy-induced nausea and vomiting (CINV) market.

The high cost of drugs used to prevent or treat chemotherapy-induced nausea and vomiting (CINV) is having a significant impact on market growth. These elevated costs can limit patient access to treatment and consequently reduce the overall demand in the chemotherapy-induced nausea and vomiting (CINV) market. For example, a study published by the National Center for Biotechnology Information (NCBI) in September 2022 estimated the cost of managing a CINV episode per cycle of chemotherapy at €31.51 per patient. This study also revealed the mean cost per patient per severe CINV episode, which amounted to approximately €389 in Italy, €750 in France, and €1017 in Germany, highlighting the substantial cost of drugs and treatment. As a result, the high cost of CINV drugs is impacting the growth of the chemotherapy-induced nausea and vomiting (CINV) market.

Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are at the forefront of introducing innovative products, particularly transdermal delivery systems (TDS), to cater to the market's evolving needs. A transdermal delivery system (TDS) is a drug delivery method that enables controlled medication release through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a U.S.-based biotechnology company, announced the FDA's approval of STAR-OLZ, a transdermal delivery system (TDS) for treating chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) designed to cover the entire five-day CINV therapy duration. Independent double-blind trials have demonstrated that olanzapine, an active component, is a highly effective antiemetic, surpassing other standard-of-care treatments, including NK1 receptor antagonists, in terms of nausea management. STAR-OLZ previously underwent Phase 1 in-human bioavailability (BA) trials, confirming its local tolerability over a 5-day dosing interval and delivering approximately 60% less medication than the oral form.

In January 2022, Cumberland Pharmaceuticals Inc., a U.S.-based specialty pharmaceutical firm, acquired SANCUSO (granisetron transdermal patch) from Kyowa Kirin Inc. for $13.5 million. This acquisition granted Cumberland full control over the U.S. rights to SANCUSO, a chemotherapy-induced nausea and vomiting (CINV) drug. This included responsibility for marketing, promotion, distribution, manufacturing, and medical support operations related to the product. Kyowa Kirin Inc. is a U.S.-based subsidiary of Kyowa Kirin Co. Ltd. in Japan, a specialty pharmaceutical company that specializes in developing innovative medicines used for preventing CINV.

Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2023. The regions covered in chemotherapy-induced nausea and vomiting (CINV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chemotherapy-induced nausea and vomiting (CINV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

CINV presents in various forms, including injectables, oral medications, and transdermal patches. Injectables are chemical substances administered via injection to produce various therapeutic effects. Medications used for CINV management belong to different drug classes, such as 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and others. The risk of developing CINV varies, with emetogenic risks categorized into highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC), and low emetogenic chemotherapy (LEC). These treatments and medications are distributed through multiple channels, including CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies, and drug stores. They find application in various medical fields such as gynecology, urology, gastrointestinal surgery, and others.

This report provides chemotherapy-induced nausea and vomiting (CINV) market statistics, including chemotherapy-induced nausea and vomiting (CINV) industry global market size, regional shares, competitors with a chemotherapy-induced nausea and vomiting (CINV) market share, detailed chemotherapy-induced nausea and vomiting (CINV) market segments, market trends and opportunities and any further data you may need to thrive in the chemotherapy-induced nausea and vomiting (CINV) industry. This chemotherapy-induced nausea and vomiting (CINV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced nausea and vomiting (CINV) market consists of revenues earned by entities by providing services such as pharmacologic therapy and nonpharmacologic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced nausea and vomiting (CINV) market also includes the sales of such as olanzapine, dexamethasone, cannabinoids, metoclopramide, promethazine and prochlorperazine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.